SCHEMBL4775349

SCHEMBL4775349

COCc1ccc(N(Cc2cccc(Cl)c2Cl)S(C)(=O)=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
POLB P06746 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.39
PER2 O15055 1/20 0.39
CRY1 Q16526 1/20 0.39
CRY2 Q49AN0 1/20 0.39
ALDH1A1 P00352 3/20 0.39
PTPN1 P18031 2/20 0.38
PTPN6 P29350 1/20 0.38
PTPN11 Q06124 1/20 0.38
RECQL P46063 1/20 0.38
KDM4E B2RXH2 2/20 0.38
IDO1 P14902 2/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NR1H4 Q96RI1 1/20 0.36
HPGD P15428 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772377 0.86 PNMT (0.47) LMNAPOLBGAAMAPTALDH1A1
SCHEMBL4777413 0.85 KDM4E (0.52) LMNAPOLBGAAMAPTPER2
SCHEMBL4777644 0.85 GAA (0.45) LMNAPOLBGAAMAPTALDH1A1
SCHEMBL4771201 0.84 LMNA (0.50) LMNAPOLBGAAMAPTCRY1
SCHEMBL4773148 0.83 ALDH1A1 (0.56) LMNAPOLBGAAALDH1A1PTPN1
SCHEMBL4777553 0.83 ALDH1A1 (0.49) LMNAPOLBGAAMAPTPER2
SCHEMBL4773540 0.81 GAA (0.43) LMNAPOLBGAAMAPTALDH1A1
SCHEMBL4777409 0.81 ALDH1A1 (0.51) LMNAPOLBGAAMAPTALDH1A1
SCHEMBL4775267 0.80 ALDH1A1 (0.52) LMNAGAAMAPTALDH1A1KDM4E
SCHEMBL4769790 0.79 KDM4E (0.44) LMNAPOLBGAAMAPTPER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 LMNA 1022/4885POLB 292/4885GAA 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.